N-Acetylcysteine Use to Prevent Contrast Medium-induced Nephropathy: Premature Phase III Trials

David A. Stenstrom, Leslie L. Muldoon, Hector Armijo-Medina, Suzanne Watnick, Nancy D. Doolittle, John A. Kaufman, Darryl R. Peterson, Joseph Bubalo, Edward A. Neuwelt

Research output: Contribution to journalReview article

18 Scopus citations

Abstract

To date there has been no general consensus regarding the effectiveness of N-acetylcysteine as a protective therapy against contrast medium-induced nephropathy. Several phase III clinical trials have been conducted without a proper understanding of N-acetylcysteine pharmacology, particularly with regard to first-pass hepatic metabolism. A review was conducted of the literature concerning contrast medium-induced nephropathy and new studies of human N-acetylcysteine pharmacology were performed. After an analysis was performed, it was concluded that further phase I and phase II trials are needed. The efficacy of N-acetylcysteine in the prevention of contrast medium-induced nephropathy may be demonstrated with the use of higher doses than used in earlier studies, in combination with parenteral administration.

Original languageEnglish (US)
Pages (from-to)309-318
Number of pages10
JournalJournal of Vascular and Interventional Radiology
Volume19
Issue number3
DOIs
StatePublished - Mar 1 2008

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'N-Acetylcysteine Use to Prevent Contrast Medium-induced Nephropathy: Premature Phase III Trials'. Together they form a unique fingerprint.

  • Cite this